Glenmark shines on declaring top-line results from Phase 3 clinical trial of favipiravir for COVID-19 treatment

23 Jul 2020 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs. 424.95, up by 11.25 points or 2.72% from its previous closing of Rs. 413.70 on the BSE.

The scrip opened at Rs. 421.25 and has touched a high and low of Rs. 430.50 and Rs. 421.25 respectively. So far 205948 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 572.70 on 22-Jun-2020 and a 52 week low of Rs. 168.00 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 435.50 and Rs. 408.00 respectively. The current market cap of the company is Rs. 11673.30 crore.

The promoters holding in the company stood at 46.62%, while Institutions and Non-Institutions held 28.93% and 24.44% respectively.

Glenmark Pharmaceuticals has declared top-line results from a Phase 3 clinical trial in mild to moderate COVID-19 patients conducted across seven clinical sites in India. The open-label randomized, multicenter clinical trial, conducted in 150 patients, evaluated the efficacy and safety of Favipiravir plus standard supportive care (Favipiravir treatment arm), versus standard supportive care alone (control arm), in mild to moderate patients, randomized within a 48 hour window of testing RT-PCR positive for COVID-19.

Favipiravir is a broad spectrum oral antiviral drug that selectively inhibits RNA-dependent RNA polymerase (RdRp) and the viral replication phase of SARS-CoV-2, and is being studied in multiple ongoing international clinical trials. Patients in the Glenmark Favipiravir clinical trial received Favipiravir tablets 3,600 mg (1,800 mg BID) (Day 1) + 1,600 mg (800 mg BID) (Day 2 or later) for up to maximum of 14 days, along with standard supportive care. Randomization was stratified based on disease severity into mild (90 patients) and moderate (60 patients).

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

1974.05 17.65 (0.90%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×